SpaceX Just Joined the Nasdaq-100. Is It Time to Buy?

SpaceX’s addition to the Nasdaq-100 should force index-tracking funds to buy shares, but the stock “barely budged” and recently declined. The article flags valuation risk—SpaceX generated $18.7B revenue in 2025 (+33%) but trades at ~104x sales—and notes it is now below its $150 IPO debut price. A tiered lockup expiring over the next year could increase selling pressure and volatility as insiders gain the ability to sell, potentially capping upside until profitability/earnings clarity improves.

Analysis

The market is treating this more like a sentiment test than a fundamentals event. A one-time index inclusion that fails to move the stock usually means the marginal passive buyer is already exhausted, so the next real price-setter is not flow but supply. In that setup, the first staged insider unlocks tend to matter more than the headline catalyst because they create a slow, persistent overhang that can compress multiples for quarters, not days.

The key mechanism is valuation fragility: when a name is priced on extreme sales multiples with no earnings anchor, even solid growth can be insufficient if the path to profitability is opaque. That creates asymmetric downside if future prints merely confirm growth without margin leverage, because the market then starts discounting slower future expansion rather than rewarding current scale. The second-order effect is on adjacent late-stage private growth names: investors may become more selective on secondary deals and demand wider discounts for illiquid paper.

Contrarianly, the consensus may be underestimating how much supply can be absorbed if strategic buyers or crossover funds want a long-duration asset with scarcity value. The bullish reversal case is not the index event; it is a demonstrably better quarterly report plus evidence that unlock supply is being digested without a discount. Until then, this looks more like a patience trade than an urgency trade, with the burden of proof on the company to prove that growth can outpace dilution of enthusiasm.

Key Decisions for Investors

• Avoid chasing SPCX on the index-inclusion narrative; if anything, fade any strength into the next liquidity event. Time horizon: 1-3 months. Falsifier: a post-unlock secondary that clears at minimal discount and the next print shows clear operating leverage.
• For any private-market exposure holders, reduce or hedge ahead of the tiered lockup window rather than waiting for the first large unlock. Risk/reward: better to sell into residual scarcity than into forced supply.
• Relative-value expression: long NVDA / short ARKK as a quality-vs-narrative growth pair over the next 1-3 months. Thesis: the market should continue rewarding profitable secular growth while punishing the most expensive non-earning names.
• Set a watch item on SPCX for the next quarterly update: if revenue growth remains >30% but margin trajectory stays absent, treat that as a signal to stay underweight despite headline expansion. If growth re-accelerates and profitability visibility improves, the bearish supply-overhang thesis weakens materially.
• Do not initiate a standalone NDAQ position on this event; the fee/flow uplift from passive ownership is too small to matter versus the one-time nature of the catalyst. Any pop in NDAQ should be viewed as tradeable noise, not a durable fundamental rerating.